Overview: This presentation (this "Presentation") dated November 17, 2025, has been prepared by Southern Cross Gold Consolidated Ltd ("SXGC" or the "Company") and is authorized for release by Managing Director, Michael Hudson. Sunday Creek An Expanding and Significant Global Gold Discovery Michael Hudson Managing Director AGM - 17 November 2025 For personal use only Accuracy of Information: Readers are directed to the public disclosure of Southern Cross Gold Consolidated Ltd ("SXGC") available under SXGC's ...

Financial Data and Key Metrics Changes - Total revenue for the first nine months of 2025 was approximately $2.8 million, a decrease of about $1 million or 27% compared to $3.8 million in the same period in 2024, reflecting a strategic shift away from legacy contract work [18] - Cost of revenue rose to approximately $2.8 million, a 48% increase from $1.9 million during the first nine months of 2024 [18] - Gross loss for the period was approximately $4 million, compared to a loss of about $719,000 in the same period last year [19] - Selling general and administrative expenses totaled $13 million, compared to $9.9 million in the prior year, reflecting key growth initiatives [20] - Net loss for Q3 2025 was $6 million compared to $3.9 million in the same period of the prior year [24] Business Line Data and Key Metrics Changes - The company is transitioning from legacy high-margin contracts to higher-value commercial space-based and AI-driven solutions, which is expected to generate more sustainable recurring revenue in future periods [18] - The gross loss increase was primarily due to higher depreciation from recently capitalized assets and reduced contributions from legacy services [23] Market Data and Key Metrics Changes - The company is seeing strong momentum internationally, especially among allies seeking sovereign U.S. origin multi-domain capabilities [31] - Greater budget clarity within the U.S. is helping stabilize and improve program timelines, which is viewed as an upside [31] Company Strategy and Development Direction - The company is evolving into a diversified space and defense innovator, focusing on full-spectrum solutions from design and manufacturing to on-orbit operations and data services [5] - The vertically integrated model enables scalability and efficiency, allowing rapid entry into new markets and development of recurring revenue streams [10] - The company is strategically investing in infrastructure, technology, and team to build capabilities comparable to larger competitors with less capital [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience and adaptability regardless of external landscape challenges, including government funding uncertainties [7] - The company is positioned to meet rising global demand for resilient, secure, and cost-effective space capabilities [11] - The recent capital raises are intended to fund product commercialization, LISIS-AT scaling, and AI development [32] Other Important Information - The company completed two successful capital raises, receiving approximately $15.5 million of net proceeds [24] - The LISIS-AT platform is increasingly software-defined, enabling rapid in-orbit reconfiguration and performance optimization [11] Q&A Session Summary Question: What is the commercialization timeline for Fortis VPX? - The first three VPX products remain on track for release to production in January of 2026, with customer integrations and revenue contributions expected shortly thereafter [29] Question: Can you update on the commissioning timeline for LISIS-AT 3? - The commissioning is progressing well, with multiple payloads and sensors, and additional satellites in production will expand hosted payload capability and data availability [30] Question: Are customers already evaluating Fortis VPX or FeatherEdge? - Active early access programs are in place with both government and commercial customers, with several transitioning toward multi-year hardware agreements [31] Question: What does your geographic revenue mix look like going forward? - Strong momentum is seen internationally, especially among allies, with greater budget clarity in the U.S. improving program timelines [31] Question: How does the recent capital raise position the company? - The capital raise funds a significant portion of near-term product commercialization, LISIS-AT scaling, and AI development [32] Question: Can you expand on alignment with the DOD's Golden Dome vision? - The company's technology roadmap aligns directly with the DOD's Golden Dome vision, focusing on resilient, distributed, multi-layered sensing and communications architecture [32] Question: What is the potential market for your lunar-capable LISIS-AT Lunar platform? - The company believes its early mover position creates a strategic opportunity in the expanding lunar exploration and infrastructure programs [33]

Financial Data and Key Metrics Changes - The company reported revenues of $303,000 for the quarter, representing a 51% increase compared to the same quarter last year [8] - For the first half of the fiscal year, revenues increased by 85% to over $600,000, marking the best first half ever for the company [5][8] - Gross profit totaled $220,000, or 72.6% of revenues, which was a 23% increase from $180,000, or 89.5% of revenues in the same quarter a year ago [9] - Net loss totaled $3 million, or $0.11 per share, compared to a net loss of $2.2 million in the same quarter last year [10] - Available cash increased to $768,000 from $220,000 at the end of the previous fiscal year [11] Business Line Data and Key Metrics Changes - The U.S. distributor network increased sales by 35% year-over-year, contributing $237,000, or 75% of total revenues for the quarter [4][8] - The new product, Precise PRP, generated increased revenue during the quarter, with 42% of revenue attributed to PRP and 58% to Spring [34] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a CAGR of 11%, reaching approximately $2.4 billion in six years [3] - The European animal market is estimated at over $16.56 billion and is projected to grow at a CAGR of 8.6% [3] - The U.K. market exceeds $2.6 billion and is growing at a 7.8% CAGR [4] Company Strategy and Development Direction - The company aims to expand the use of its flagship product, Spring, and increase awareness of Precise PRP for treating osteoarthritis in animals [13] - The company is exploring the introduction of products to human markets and has formed partnerships to enhance its market presence [7][18] - A strategic collaboration with Digital Landia aims to integrate AI technology into the company's platform, enhancing diagnostic capabilities [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong sales momentum and market penetration for the remainder of fiscal 2026 [27] - The company anticipates another year of record growth and improving bottom line as it expands the use of Spring and Precise PRP [27] - The third and fourth quarters are expected to be particularly strong due to increased industry events driving product awareness [28] Other Important Information - The company qualified to begin trading on the OTCQX best market, enhancing visibility and liquidity for investors [12] - The appointment of Josh Rubin to the board of directors is expected to provide valuable insights into growth-stage companies [6] Q&A Session Summary Question: How many clinics are heavy users of the product? - The learning curve for veterinarians to adopt the product ranges from six months to a year, with anecdotal evidence showing continued growth in adoption [32] Question: Can you break down the revenue between Spring and PRP? - Approximately 42% of revenue was from PRP and 58% from Spring, with the PRP revenue only reflecting the canine version as equine shipments just began [34][35] Question: Do you have any corporate clinics that have adopted your product corporate-wide? - No corporate-wide adoption has occurred yet, as each corporate clinic allows veterinarians to make their own decisions [37] Question: Can you provide a breakdown between companion versus equine revenue? - The company tracks these markets separately and plans to provide more detailed segment reporting in the future [39]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 totaled approximately $384,000, a significant increase from $101,000 in the same period last year, primarily due to growth in research and development services contracts and custom hardware contracts [13] - Gross margin improved to 33% compared to 9% in Q3 2024, although variability is expected due to a small number of active contracts [14] - Net income for Q3 2025 was $2.4 million, or approximately $0.01 per share, compared to a net loss of $5.7 million in Q3 2024 [16] - Total assets increased to $898 million as of September 30, 2025, up from $154 million at year-end 2024 [17] Business Line Data and Key Metrics Changes - The company recorded revenue from the NASA LIDAR initiative and completed a transaction with a major U.S. financial institution, validating its quantum AI and security platforms [7] - Revenue recognition began for cloud-based access to the Direct3 quantum optimization system during Q3 [14] Market Data and Key Metrics Changes - The company is seeing growing adoption of quantum and photonic solutions across research, enterprise, and government sectors, indicating a positive trend in market demand [7] - The integrated photonics platform is positioned to address global energy constraints and computational demands, making it relevant for various sectors [11] Company Strategy and Development Direction - The company aims to transition from prototype and small-batch manufacturing to volume production by the end of the decade, focusing on refining processes and expanding facilities [5][12] - The long-term strategy includes evaluating acquisition opportunities to accelerate the vision of making quantum technology accessible [15] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of scaling engineering and manufacturing capabilities and strengthening relationships across government, industry, and academia [19] - The company is positioned to deliver energy-efficient room-temperature quantum devices, which are critical for the next generation of computing [11] Other Important Information - The company raised $500 million in Q3 and an additional $750 million post-quarter, significantly strengthening its balance sheet [3][15] - Operating expenses increased to $10.5 million in Q3 2025, reflecting growth in personnel across various departments [16] Q&A Session Summary Question: Details on Poet Technologies partnership - Management discussed active talks with multiple parties on using thin-film lithium niobate technology for high-speed transceiver technology, highlighting the collaboration with Poet Technologies [22] Question: Use cases for quantum security solutions - Management mentioned discussions with firms to apply quantum communication technology to aerospace platforms and the potential for smaller quantum communication systems [23][24] Question: M&A opportunities and market conditions - Management acknowledged the volatile M&A market and is actively evaluating acquisition candidates to enhance customer revenue and technology roadmap [26][27] Question: CapEx for Fab 1 and plans for Fab 2 - Fab 1 is fully operational with an additional CapEx of about $2 million planned for high-speed testing equipment, while Fab 2 is being scoped for both internal needs and external demand [35][36] Question: International opportunities - Management confirmed active discussions for international partnerships and sales, including projects in Europe and South Korea [57]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 totaled approximately $384,000, a significant increase from $101,000 in the same period last year, primarily due to growth in research and development services contracts and custom hardware contracts [13] - Gross margin improved to 33% in Q3 2025, compared to 9% in Q3 2024, although variability is expected due to a small number of active contracts [14] - Net income for Q3 2025 was $2.4 million, or approximately $0.01 per share, compared to a net loss of $5.7 million in Q3 2024 [16] - Total assets increased to $898 million as of September 30, 2025, up from $154 million at year-end 2024 [17] Business Line Data and Key Metrics Changes - The company recorded revenue from its NASA LiDAR initiative, showcasing the practical application of its quantum technology [7] - Revenue recognition began for cloud-based access to the Dirac-3 quantum optimization system during Q3 [14] - Significant commercial engagements included a transaction with a major U.S. financial institution, validating the company's quantum AI and security platforms [7] Market Data and Key Metrics Changes - The company is actively engaging with various sectors, including aerospace, defense, telecommunications, finance, and data security, to expand the adoption of its quantum solutions [4] - The integrated photonics approach allows for room temperature operation, making the technology more accessible and scalable across industries [4][11] Company Strategy and Development Direction - The long-term goal is to transition from prototype and small-batch manufacturing to volume production by the end of the decade [5] - The current three-year roadmap focuses on refining processes, scaling production, and expanding the team and facilities to support industrial-scale output [5][12] - The company aims to leverage its thin-film lithium niobate technology for next-generation high-speed transceiver technology, indicating a strategic focus on telecommunications [22] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of scaling engineering and manufacturing capabilities to meet growing demand and drive future growth [19] - The company is positioned to deliver energy-efficient room-temperature quantum devices, which are critical for the next generation of computing [11] - Management expressed confidence in the company's ability to navigate the evolving landscape of quantum technology and maintain a competitive edge [19] Other Important Information - The company raised $500 million in Q3 2025 and an additional $750 million post-quarter, significantly strengthening its balance sheet [3][15] - Operating expenses increased to $10.5 million in Q3 2025, reflecting growth in personnel across various functions to support expansion [16] Q&A Session Summary Question: Details on partnership with POET Technologies - Management confirmed active discussions with multiple parties regarding the use of thin-film lithium niobate technology for high-speed transceiver applications, highlighting the collaboration with POET as a significant opportunity [21][22] Question: Use cases for quantum security solutions - Management discussed ongoing discussions with firms to apply quantum communication technology in various sectors, including aerospace, indicating a broad interest beyond security solutions [23][24] Question: M&A opportunities and market conditions - Management acknowledged the volatility in the M&A market but confirmed active evaluation of acquisition candidates to accelerate commercialization and fill technology gaps [25][26] Question: CapEx for Fab 1 and plans for Fab 2 - Management indicated that Fab 1 is fully operational with plans for additional CapEx of about $2 million for high-speed testing equipment, while Fab 2 is being scoped for both internal needs and external demand [34][36] Question: International opportunities - Management confirmed ongoing efforts to explore international markets, including sales to institutions in Europe and partnerships in South Korea [58]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in iHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year-over-year in life sciences and food safety [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIT solution sales increased by 21% year-to-date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide positions the company to serve not only life sciences and healthcare but also agriculture, food processing, and environmental biosafety [7][23] - The active pipeline surpassed $15 million, encompassing both domestic and international customers across various industries [6] Company Strategy and Development Direction - The company aims to enhance customer engagement and expand its recurring revenue streams through personalized outreach and targeted marketing campaigns [8] - Focus on biosecurity advancements and scaling automation integrations for high-efficacy environments is prioritized for 2026 [8][9] - The company is investing in innovation and customer success to capture opportunities in clean tech and biosecurity [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and reaffirmed the soundness of its strategy, with steady improvement expected financially, operationally, and strategically [25][26] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26][27] Other Important Information - The company celebrated a significant addition to its customer roster with Bausch + Lomb, which adopted mobile handheld surface units and committed to BIT Solution orders for 2026 [19][20] - The company is actively pursuing the cannabis market and has opened doors to promising new partnership discussions [22] Q&A Session Summary Question: What are your sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [29] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins expected to hold steady [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while there was a decrease in solution sales growth in Q3, they expect a rebound by the end of the fourth quarter [35] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, with expectations for significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in device manufacturing for this purpose [51]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in IHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year over year in the life sciences and food safety areas [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIP solution sales increased by 21% year to date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide as a safe disinfectant opens new markets, particularly in food processing and agriculture [7][23] - The company is seeing strong interest from emerging sectors, with an active pipeline surpassing $15 million [6][7] Company Strategy and Development Direction - The company aims to grow sales of mobile capital equipment, IHP corporate service, and custom integration platforms alongside its core BIP solution business model [5][8] - There is a focus on biosecurity advancements and scaling automation integrations for high-efficacy environments, addressing global challenges [8][9] Management's Comments on Operating Environment and Future Outlook - Management believes the third quarter marked a decisive turning point, with a 95% sequential revenue increase driven by expanding recurring revenue streams [4][5] - The company is optimistic about the future, with a strong sales backlog and a sales strategy beginning to deliver promising results [25][26] Other Important Information - The company entered into an equity purchase agreement with Hudson Global Ventures, allowing it to sell up to $20 million in common stock over a 24-month period [26] - The SteraMist IHP technology was named the Disinfection and Decontamination Products Company of the Year 2025 [7] Q&A Session Summary Question: What are the sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management sees the food industry as a key marketing vertical and is excited about the approval, which is expected to be a game changer [29] Question: Should operating expenses and gross margins continue to improve? - Management expects operating expenses to increase but believes they will be positive in relation to revenue, with gross margins remaining stable [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has different distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: What visibility is there on solution sales in the coming quarters? - Management anticipates that solution sales will increase as more technology is deployed, with a key focus on driving growth in BIP solution sales [35] Question: Any updates on servicing military and defense markets? - The company is working with a key site looking to replace formaldehyde and expects significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical instrument sterilization? - The company is prioritizing partnerships in device manufacturing to streamline IHP into decontamination processes [51]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 totaled approximately $384,000, compared to $101,000 in the same period last year, primarily due to increases in research and development services contracts and custom hardware contracts [12][14] - Gross margin for Q3 increased to 33% compared to 9% in Q3 2024, although variability is expected due to a small number of active contracts [14] - Net income for Q3 was $2.4 million, or approximately $0.01 per share, compared to a net loss of $5.7 million in Q3 2024 [16] - Total assets stood at $898 million at the end of Q3 2025, up from $154 million at year-end 2024 [17] Business Line Data and Key Metrics Changes - The company recorded revenue from the NASA LIDAR initiative and completed a transaction with a major U.S. financial institution, validating its quantum AI and security platforms [6][7] - The foundry operations in Tempe, Arizona, continue to progress, with plans for Fab 2 to support higher volume manufacturing [8][12] Market Data and Key Metrics Changes - The company is seeing growing adoption of quantum and photonic solutions across research, enterprise, and government sectors, with increasing interest from prospective customers [10][11] - International opportunities are being explored, with sales to institutions in Europe and discussions with potential partners in South Korea and Singapore [37] Company Strategy and Development Direction - The long-term goal is to transition from prototype and small-batch manufacturing to volume production by the end of the decade, focusing on refining processes and expanding facilities [5][12] - The company aims to position itself uniquely in the market by leveraging its integrated photonics platform, which operates at room temperature and offers significant SWaP-C advantages [11] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of scaling engineering and manufacturing capabilities, advancing customer programs, and strengthening relationships across various sectors [18] - The company is actively evaluating acquisition opportunities to accelerate its vision of making quantum technology accessible [15][16] Other Important Information - The company raised $500 million in Q3 and an additional $750 million post-quarter, significantly strengthening its balance sheet [3][15] - Operating expenses for Q3 totaled $10.5 million, up from $5.4 million in the same quarter last year, driven by growth in personnel across various functions [16] Q&A Session Summary Question: Details on Poet Technologies partnership - The company is actively discussing using thin-film lithium niobate technology for next-generation high-speed transceiver technology, with Poet Technologies being one of the collaborations [20][21] Question: Use cases for quantum security solutions - Discussions are ongoing with firms to apply quantum communication technology to various sectors, including aerospace and telecommunications [22] Question: Remaining CapEx for Fab 1 - Fab 1 is fully operational, with an additional CapEx of about $2 million planned for high-speed testing equipment [25][26] Question: Plans for Fab 2 - Fab 2 is being scoped to support both the company's quantum machine manufacturing and to serve external demand for thin-film lithium niobate chips [26] Question: Share count at the end of 2026 - The company currently has 224 million shares outstanding and does not expect to conduct another financing, with a potential increase of a few million shares from options [27][28] Question: International opportunities - The company is exploring international markets and has made sales to institutions in Europe and discussions in South Korea [37]

Financial Data and Key Metrics Changes - Q3 2025 revenue was $2.8 million, a 163% increase year-over-year from $1.1 million in Q3 2024 [6][22] - Net loss decreased to $5.9 million, a 62% improvement compared to $15.4 million in the prior year quarter [6][24] - Shareholders' equity increased by 72% to $5.4 million [7] - Gross margin was 81.7%, up 1,302 basis points from 68.7% in Q3 2024 [24] - Annual recurring revenue (ARR) reached $11 million, representing a 168% increase from $4.1 million in Q3 2024 [22][25] Business Line Data and Key Metrics Changes - The company reported a gross profit of $2.3 million for Q3 2025, an increase of 213% from $0.7 million in Q3 2024 [24] - Total operating expenses for Q3 2025 were $6.8 million, up from $3.5 million in Q3 2024, primarily due to the addition of OpenReel and Videlo [24][26] Market Data and Key Metrics Changes - The company serves over 140,000 customers across various sectors, including healthcare, financial services, e-commerce, and technology [16][17] - Significant traction was noted in the banking, financial services, and insurance sectors, with a focus on mid-market and enterprise segments [17][50] Company Strategy and Development Direction - The company is focused on building and acquiring products in four key areas: attracting leads, engagement, tracking, and intelligence [5][14] - A strategic acquisition of Superblocks was announced, aimed at enhancing the AI platform for marketing [12][13] - The company aims to reduce balance sheet leverage and improve cash position through organic growth and M&A [15][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory and the positive impact of recent debt conversions on future financials [7][8] - The focus remains on generating sustainable value for shareholders and improving cash flow for reinvestment in growth [34][43] Other Important Information - The company secured an $11 million debt facility to support acquisitions and operations [8] - The appointment of new leadership, including a Chief Financial Officer and a VP of Sales, is expected to drive strategic growth [12][16] Q&A Session Summary Question: Did the company experience seasonality in Q3 compared to Q2? - Management noted that the market was stronger in Q3, with a shift from one-time license revenue to recurring revenue in the Create Studio business [35][36] Question: What are the pipeline expectations? - Management highlighted substantial improvements in the pipeline, especially in the banking and financial services sectors, with several seven-figure deals in progress [38][50] Question: What does the M&A market look like now? - Management indicated attractive valuations and a healthy M&A market, with ongoing opportunities being evaluated [39][40] Question: Can the company comment on expected cross-sell or upsell uplift? - Management expressed optimism about the Superblocks acquisition providing significant upsell opportunities, particularly for mid-market and enterprise customers [41][42] Question: What operational financial milestones should investors look for? - Key catalysts include continued improvement in net income and ARR, alongside the completion of debt cleanup [43][44]

Financial Data and Key Metrics Changes - Total revenues for Q2 2026 were $12.7 million, down 3% from the prior year quarter, but would have been $13.4 million, up 5%, if a $1.1 million licensing deal for the Toxic Avenger was recognized [5][14] - Operating margins improved by 7% from the prior year quarter to 58% [5] - Net loss for the quarter was $5.5 million, compared to a net loss of $1.2 million in the prior year quarter [15] - Adjusted EBITDA was negative $3.7 million, down from positive $0.5 million in the prior year quarter [15] - Cash and cash equivalents were $2.3 million as of September 30, with $5.9 million available on a $12.5 million working capital facility [15][16] Business Line Data and Key Metrics Changes - The performance of the Toxic Avenger Unrated was below expectations at the box office, but it is expected to be profitable with an IRR of 40% due to strong ancillary distribution [6][9] - The company continues to focus on controlling costs and leveraging efficiencies from Cineverse Services India to manage SG&A spending [6] - The upcoming releases, Silent Night Deadly Night and Return to Silent Hill, are projected to follow a similar low-cost investment strategy [9] Market Data and Key Metrics Changes - Total streaming viewers reached 143.8 million, up 47% year over year, with total minutes streamed at 3.4 billion, up 45% [18] - SVOD subscribers grew to 1.39 million, a 6% increase year over year [18] - The Cineverse branded channel grew more than 6,400% in viewership since its relaunch in January [19] Company Strategy and Development Direction - The company is focusing on a fan-centric, IP-based film strategy, avoiding mixed-genre films in the future [31] - The Match Point technology sales pipeline is expanding, with dozens of potential partners actively evaluating the technology [12][23] - The MicroCo joint venture aims to become a leader in the micro-drama market, which is expected to represent a significant portion of streaming viewing time [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that investments made in sales, marketing, and technology will yield strong results in the remainder of the fiscal year and beyond [15][17] - The advertising environment is mixed, but there is optimism for growth as political spending ramps up in Q4 [20][21] - The company believes it is well-positioned for future growth with multiple engines of growth supported by technology and a growing audience [26] Other Important Information - The content library is now valued at $45 million, significantly above the $3.2 million book value [12][16] - The company is actively seeking strategic partnerships and acquisitions to enhance its technology offerings [24][40] Q&A Session Summary Question: Impact of Toxic Avenger's performance on future slate - Management believes the performance validated their theatrical releasing strategy and will influence future film selections to avoid mixed-genre movies [30][31] Question: Timing of monetization for Match Point - Management indicated that while the sales cycle is longer, there is strong interest from studios, and they expect significant revenue contributions in the next 12-24 months [32][33]